Clinical and radiologic evaluation of a Turkish family with hypochondroplasia and a rare FGFR3 variant
Author:
Ekinci Sadiye1, Ülger Yasemin1, Acar Mustafa Oğuz1, Ceran Ayşegül2, Aycan Zehra2, Fitoz Ömer Suat3, Ilgın Ruhi Hatice1
Affiliation:
1. Medical Genetics Department , Ankara University School of Medicine , Ankara , Turkey 2. Pediatric Endocrinology Department, Ankara University School of Medicine , Ankara , Turkey 3. Radiology Department, Ankara University School of Medicine , Ankara , Turkey
Abstract
Abstract
Objectives
Hypochondroplasia (HCH) is characterized by disproportionate short stature and regarded as a milder form of achondroplasia (ACH), which is another skeletal dysplasia, both caused by variants in fibroblast growth factor receptor 3 (FGFR3) gene. HCH diagnosis is based on the clinical features and skeletal survey findings. The most common FGFR3 variant in HCH affects the codon 540, leading to substitution of asparagine with lysine in about 70% of patients.
Case presentation
Herein, we described the clinical and radiographical manifestations of HCH in affected members of a Turkish family with very rare Asn540Thr (c.1619A>C) variant within hot spot of the gene for this condition.
Conclusions
This is a very rarely reported variant in the literature and this report is the first case with this variant in Turkish population. The report also presents the phenotypic variability within a family with the same variant, which is inherent to HCH.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference11 articles.
1. Wen, X, Li, X, Tang, Y, Tang, J, Zhou, S, Xie, Y, et al.. Chondrocyte FGFR3 regulates bone mass by inhibiting osteogenesis. J Biol Chem 2016;291:24912–21. https://doi.org/10.1074/jbc.m116.730093. 2. Chang, IJ, Sun, A, Bouchard, ML, Kamps, SE, Hale, S, Done, S, et al.. Novel phenotype of achondroplasia due to biallelic FGFR3 pathogenic variants. Am J Med Genet 2018;176:1675–9. https://doi.org/10.1002/ajmg.a.38839. 3. Deng, C, Wynshaw-Boris, A, Zhou, F, Kuo, A, Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996;84:911–21. https://doi.org/10.1016/s0092-8674(00)81069-7. 4. Xue, Y, Sun, A, Mekikian, PB, Martin, J, Rimoin, DL, Lachman, RS, et al.. FGFR3 mutation frequency in 324 cases from the international skeletal dysplasia registry. Mol Genet Genomic Med 2014;2:497–503. https://doi.org/10.1002/mgg3.96. 5. Ornitz, DM, Itoh, N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015;4:215–66. https://doi.org/10.1002/wdev.176.
|
|